Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States

Achilles Therapeutics plc (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, has announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share of the Company. All ADSs to be sold in the proposed IPO will be offered by Achilles.  The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.

For further details visit the Achilles website.